We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Fast, Fully Automated Microfluidic Device Predicts Effectiveness of Cancer Treatment

By LabMedica International staff writers
Posted on 03 Apr 2023
Print article
Image: New microfluidics physics-based device to predict cancer therapy response (Photo courtesy of University of Barcelona)
Image: New microfluidics physics-based device to predict cancer therapy response (Photo courtesy of University of Barcelona)

Designing new technologies for personalized cancer treatment is a significant challenge in the ongoing battle against cancer. Tumors possess unique characteristics and predictive indicators of a patient's response to treatment, based on the tumor's molecular characteristics, such as DNA mutations, is a crucial step forward in oncology. Precision medicine seeks to provide a tailored treatment for cancer patients, both adult and pediatric, that is specific to their pathology. Determining whether a patient can benefit from a particular treatment before initiating therapy could provide a boost to personalized cancer treatment. Now, a microfluidic device can quickly and automatically predict the effectiveness of cancer treatment by using a tiny amount of cells from biopsies and without the need for specialized technical staff.

The microfluidic device called microfluidic dynamic BH3 profiling (μDBP) has been developed by researchers at the University of Barcelona (Barcelona, Spain) and the Institute for Bioengineering of Catalonia (IBEC, Barcelona, Spain). The dynamic BH3 profiling (DBP) was among the first functional assays to be successfully tested for predicting treatment in various types of cancer. This system exposes cancer cells to different therapeutic options to quickly identify the most effective treatment for a patient. This approach is conceptually similar to the use of antibiograms to identify appropriate antibiotics for bacterial infections. However, the μDBP microfluidic device represents a significant improvement over previous DBP systems. This new device requires fewer cancer cells to test potential therapies, automates the process, and can be used without requiring specialized technical staff, making it easier to apply in a clinical setting.

The initial step in testing a biopsy sample involves dissociating it into individual cells using mechanical and enzymatic methods. The processed sample is then filtered to obtain individual cells, which are subjected to the desired treatments before being seeded into the microfluidic device. The use of the μDBP microfluidic platform, which contains small wells for cell seeding, reduces the number of cells required to test a treatment, making it possible to test a larger number of drugs, which is a significant breakthrough. The paper published in the journal npj Precision Oncology is the first to use microfluidics for performing the functional assay of the DBP. Unlike other versions of the assay that require expensive machinery and specialized staff, such as the high-throughput DBP with automated plates and dispensers that test hundreds of treatments, the new μDBP device is designed to test treatments in situ quickly, easily, and automatically, without the need for expensive machinery or specialized staff. The team is currently working on a new prototype of the μDBP device that incorporates technical improvements and aims to gather more experimental evidence with primary samples to demonstrate its clinical usefulness in improving the treatment of various cancers, both pediatric and adult.

“The biggest advantage of the μDBP device is also the automation of the whole process, which would help to implement this functional methodology on a clinical scale. All these advantages would ease the adoption of DBP in hospitals as a routine trial,” according to the researchers.

“DBP has been used to identify the efficacy of treatments on a preclinical and clinical scale in many different cancers, both solid and liquid. These studies have used cell lines, animal models and primary samples with high predictive ability in all cases. However, this assay has not yet been widely applied in hospitals,” said lecturer Joan Montero. “So far, several studies have found a good correlation between DBP results and clinical response in primary leukemia samples. There are currently several clinical trials underway, and we would like this technology to be implemented in hospitals in the coming years to improve cancer therapies.”

Related Links:
University of Barcelona 

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
D-Dimer Test
Epithod 616 D-Dimer Kit
Gold Supplier
Blood Ammonia Test Analyzer
Ferritin Test

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more


view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more


view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more


view channel
Image: The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models (Photo courtesy of Gestalt Diagnostics)

New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. Gestalt Diagnostics (Spokane, WA, USA) has released the... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.